Advance in chimeric antigen receptor-T cell immunotherapy for multiple myeloma
10.13200/j.cnki.cjb.004005
- VernacularTitle:嵌合抗原受体-T细胞免疫疗法在多发性骨髓瘤中的研究进展
- Author:
AN Lin
- Publication Type:Journal Article
- Keywords:
Multiple myeloma(MM);
Chimeric antigen receptor(CAR)-T cell;
Cellular immunotherapy
- From:
Chinese Journal of Biologicals
2023;36(10):1256-1262
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,considerable progress has been made in the treatment of multiple myeloma(MM).However,despite the current improved prognosis of this malignancy,it always ends in relapse and therefore new therapeutic approaches are urgently needed to overcome it.The chimeric antigen receptor(CAR)-T cells targeting B cell maturation antigen(BCMA),cluster of differentiation 19(CD19),cluster of differentiation 38(CD38) and kappa light chains have been evaluated,and have achieved remarkable results in clinical trials.However,even when MM is treated with CAR-T cell therapy,most patients eventually relapse,which is the greatest limitation of this therapy.This paperreviewedthe research progress,limitations and optimization of CAR-T cell immunotherapy in the treatment of MM.
